by Liu Qiyu

Ten years after a car accident left him with impaired hand function, a patient at Shanghai's Huashan Hospital received the world's first commercial implant of a regulator-approved invasive brain-computer interface (BCI) on July 13. The surgery utilized Neuracle Technology’s NEO system, which collects and decodes epidural brain signals to restore hand mobility through external assistive devices.

The landmark surgery took place four months after the NEO system secured Class III medical device registration from China’s National Medical Products Administration (NMPA) on March 13, 2026—making it the first implantable BCI medical device cleared for commercial prescription worldwide.

Beyond a single surgical milestone, how close is China’s BCI industry to turning experimental technology into widespread, scalable applications?

A Surge in Funding as Investors Bet on Clinical Translation

The progress in clinical applications comes as investment interest in China’s BCI sector increases.

According to IT Juzi, a Chinese technology investment database, between 2013 and May 2026, 43 Chinese BCI companies completed 104 financing rounds, raising a total of 9.37 billion yuan.

The pace of funding accelerated sharply. In the first four months of 2026 alone, financing in China’s BCI sector had already exceeded the total amount recorded for the whole of 2025.

The investment trend reflects growing expectations around the future of neurotechnology. However, most BCI companies remain in the stages of research, clinical trials or early medical application rather than large-scale commercial deployment.

The industry’s current challenge is not only developing technologies capable of reading brain signals, but also proving that these systems can provide reliable benefits for patients at acceptable costs.

State-backed “Patient Capital” Supports Long-Term BCI Innovation

A major driver behind this surge in BCI financing is a structural shift in China’s investment landscape: the growing involvement of state-backed “patient capital.”

To bridge the gap between initial clinical success and commercial viability, state-backed investors have stepped in to underwrite the high-risk, extended R&D cycles inherent to neurotechnology.

China’s National Development and Reform Commission (NDRC) and the Ministry of Finance officially launched the national venture capital guidance fund last December, as part of efforts to mobilize more patient capital for innovative and future industries. The guidance fund has a 20-year lifespan, with extended investment and exit periods designed to provide long-term funding support and greater development space for innovative firms.

Operating through three dedicated regional funds covering the Beijing-Tianjin-Hebei region, the Yangtze River Delta, and the Guangdong-Hong Kong-Macao Greater Bay Area, the national platform has already reached preliminary investment agreements covering BCI and other strategic sectors.

Regional deployment has reinforced this top-level mandate. In February 2026, Beijing unveiled the 8-billion-yuan ZGC Science City Growth Fund Phase IV, earmarking 1 billion yuan for direct investments in BCI and future industries. Concurrently, municipal platforms in Shanghai and Shenzhen established specialized funds targeting upstream bottlenecks such as flexible electrodes and high-throughput neural chips.

Research Explores Broader Healthcare Applications

Funding alone, however, cannot determine whether BCI will succeed. The next question is whether researchers can translate technological advances into practical applications.

Beyond investment and policy support, researchers are still working to expand the range of possible medical applications.

The 4th China Brain-Computer Interface Contest, held in Beijing on July 24, highlighted the growing number of researchers and institutions working on BCI-related technologies.

Co-organized by Tsinghua University, the Chinese Institute of Electronics, Beijing Capital Technology Development Group Technology Services Co., Ltd., and other organizations, the contest attracted more than 320 teams and over 1,000 researchers from more than 150 universities, research institutions and companies worldwide. Nearly 100 projects covered areas including neural decoding algorithms, lightweight signal acquisition devices and clinical adaptation.

Rehabilitation is among the areas where researchers are actively exploring the potential of BCI technologies.

A team from Yanshan University demonstrated an intelligent rehabilitation robotic hand system designed for stroke patients. The system collects patients’ EEG signals and converts their movement intentions into commands to assist finger movement training. The project remains under development and is being explored for potential clinical applications.

Similar efforts are also being made to apply BCI technologies to lower-limb rehabilitation. A team from Tianjin University has developed “Shengong-Shenxing,” a brain-controlled hybrid lower-limb exoskeleton rehabilitation robot that combines robotic assistance with functional electrical stimulation to support patients’ recovery.

The Next Challenge

Despite these converging forces—surgical firsts, surging funding, state capital, and active academic pipelines—the path to mainstream adoption remains far from effortless. The recent approval and first clinical use represent important milestones, but they do not mean that BCI has reached widespread commercialization.

Several challenges remain.

Technically, invasive devices must demonstrate long-term stability, safety and reliability. Clinically, companies need more evidence showing that BCI systems can consistently improve patients’ quality of life. Economically, developers must find ways to reduce costs and establish sustainable payment models involving hospitals, insurance providers and patients.

Ethical issues surrounding neural data privacy and human-machine interaction will also require continued attention.

For now, China’s BCI industry is entering a crucial testing phase. The technology has moved one step closer to patients, but its ultimate success will depend on whether it can move beyond isolated breakthroughs and become a practical medical tool used at scale.